In the year 2021, hearing aid manufacturer GN Hearing was meant to launch two new products. However, a failure from the company’s research and development department delayed the plans, causing both a guidance downgrade to ”around 16 percent” from earlier ”more than 25 percent” and the immediate departure of the man in charge of the team.
”We’ve matched expectations in our revised guidance. That said, I would have liked to see some things perform better in 2021. For example our R&D pipeline, and we have of course also faced headwinds from the pandemic,” CEO of GN Hearing Gitte Aabo tells MedWatch in connection with the company’s 2021 financial report on Thursday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Senior Chemical Safety Advisor 
Consultant Manager 
Quality System Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Client Talent Acquisition Specialist 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Analytical Coordinator for Analytical Development 
Key Account Manager, Europe and Asia 
Project Manager & Scrum Master 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior Manager, Clinical Trial Budget 
SAP System Specialist (Product Supply) – Business Application Services 
(Senior) Drug Substance Specialist 
Nordic Medical Affairs Manager 
Director Global Engineering